GRITSTONE ONCOLOGY INC's ticker is GRTS and the CUSIP is 39868T105. A total of 101 filers reported holding GRITSTONE ONCOLOGY INC in Q1 2021. The put-call ratio across all filers is 0.47 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $299 | -99.6% | 174 | -99.3% | 0.00% | – |
| Q1 2023 | $68,907 | -67.0% | 24,787 | -59.1% | 0.00% | – |
| Q4 2022 | $209,059 | +25.2% | 60,597 | -7.4% | 0.00% | – |
| Q3 2022 | $167,000 | +0.6% | 65,412 | -5.3% | 0.00% | – |
| Q2 2022 | $166,000 | -52.7% | 69,040 | -19.2% | 0.00% | -100.0% |
| Q1 2022 | $351,000 | -68.0% | 85,444 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $1,098,000 | +17.2% | 85,444 | -1.6% | 0.00% | 0.0% |
| Q3 2021 | $937,000 | -39.5% | 86,870 | -48.9% | 0.00% | -33.3% |
| Q2 2021 | $1,549,000 | +17.4% | 169,868 | +21.3% | 0.00% | +50.0% |
| Q1 2021 | $1,319,000 | +230.6% | 140,057 | +38.2% | 0.00% | +100.0% |
| Q4 2020 | $399,000 | -32.0% | 101,342 | -54.4% | 0.00% | 0.0% |
| Q3 2020 | $587,000 | -53.5% | 222,082 | +16.8% | 0.00% | -66.7% |
| Q2 2020 | $1,262,000 | +167.9% | 190,165 | +134.6% | 0.00% | +200.0% |
| Q1 2020 | $471,000 | – | 81,043 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 4,450,638 | $41,970,000 | 8.18% |
| Copernicus Capital Management, LLC | 37,000 | $349,000 | 5.64% |
| EcoR1 Capital, LLC | 3,421,287 | $32,263,000 | 1.43% |
| Palo Alto Investors LP | 2,298,382 | $21,674,000 | 1.24% |
| AlpInvest Partners B.V. | 226,866 | $2,139,000 | 1.06% |
| Stenahm Asset Managment Ltd | 150,000 | $1,415,000 | 1.00% |
| FRAZIER MANAGEMENT LLC | 1,030,878 | $9,721,000 | 0.78% |
| BVF INC/IL | 1,861,239 | $17,551,000 | 0.66% |
| Avidity Partners Management LP | 2,122,064 | $20,011,000 | 0.55% |
| Redmile Group, LLC | 2,448,158 | $23,086,000 | 0.32% |